Eiko Lifesciences inks pact to acquire 25.01% stake in Reflux Pharmaceuticals

18 May 2023 Evaluate

Eiko Lifesciences has entered into a Share Subscription Agreement (SSA) with Reflux Pharmaceuticals (RPPL) in connection with the acquisition of up to 19,20,000 Equity Shares being 25.01% Equity stake in RPPL in one or more tranches for a consideration of Rs 7.00 crore.

The said partnership with RPPL would benefit the company in co-developing, marketing and sourcing key Active Pharma Ingredients (APIs) and Speciality Chemicals products. Also, this partnership will help the Company to set its footprints in various Geographic areas. 

Reflux Pharmaceuticals is a private limited company involved in the manufacturing and marketing of its own Active Pharmaceutical ingredients and Intermediates (APIs). The various products manufactured by RPPL are Tolfenamic Acid, Flavoxate HCI, Diacerein, Albendazole, Carprofen, Sulindac etc.

Eiko LifeSciences is a leading manufacturer, supplier and exporter of Speciality Chemicals and Pharma Intermediates in India and Globally.


Eiko Lifesciences Share Price

50.76 -0.01 (-0.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
BASF India 4039.90
Tata Chemicals 773.85
SRF 2886.20
Pidilite Inds. 1474.70
Deepak Nitrite 1565.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×